Granulocytes are important vehicles for the dissemination of cytomegalovirus (CMV) infection. A CMV-seronegative patient with acute lymphoblastic leukaemia (ALL) received acyclovir prophylaxis and was screened for CMV infection. Owing to prolonged neutropenia and life-threatening infections following induction chemotherapy, granulocyte transfusions from a CMV-seropositive donor were indicated. Primary CMV infection, attributed to these transfusions, ensued and subsequently led to the patient's death. This case showed that acyclovir prophylaxis was not effective in preventing CMV infection in this high-risk situation. To reduce the risk of CMV disease, more effective antiviral agents are needed.
The availability of recombinant granulocyte colonystimulating factor (G-CSF) has led to a renewed interest in granulocyte transfusions to patients with prolonged neutropenia complicated by bacterial or fungal infections. [1] [2] [3] However, there has been concern about risks of granulocyte transfusions related to alloimmunisation and transmission of viruses like CMV. Owing to potential side effects of G-CSF, the donor candidates are usually sought among highly motivated family members or friends with an identical blood group. It might therefore be difficult to recruit a CMV-seronegative donor for CMV-seronegative recipients. Experience with antiviral prophylaxis in this setting is lacking. We report on the course of granulocyte transfusions in a patient with ALL that was complicated by the transmission of CMV.
Common ALL was diagnosed in a 15-year-old CMVseronegative girl in February 1997. Complete remission was induced by chemotherapy (ALL BFM 95 protocol) followed by oral maintenance therapy. In July 1998, a bone marrow (BM) aspirate revealed an early relapse leading to therapy with the ALL-REZ-BFM'96 group 4 protocol. Allogeneic BM transplantation was planned from the 16-year-old, blood group-and HLA class I-and IIidentical, CMV-seronegative sister. After the induction block in August 1998, the patient became aplastic and suffered from Escherichia coli septicaemia and pulmonary aspergillosis of the right lower lobe. Owing to these lifethreatening complications and aplasia lasting for over 5 weeks, granulocyte transfusions from the blood groupidentical father were initiated, despite positive CMV IgG test results (CMV-IgG-ELA, Medac GmbH, Wedel, Germany, and in-house indirect IFT). After G-CSF mobilisation, granulocytes were harvested and transfused three times within 1 week in September 1998. The patient's peripheral blood leucocytes (PBL) were screened weekly for CMV by qualitative nested PCR (detection limit below 10 plasmid copies) and pp65 antigen test as described. 4 Both assays were performed on 2 Â 10 5 PBL. Furthermore, prophylaxis with i.v. acyclovir (750 mg/m 2 /day) was started. Leucocyte counts rose to 1500/ml with 61% granulocytes. During the following 3 weeks, the patient improved and became afebrile. By the end of September 1998, the BM aspirate was free of leukaemic cells and maintenance therapy ensued. At 4 weeks after the first granulocyte transfusion, the patient became thrombocytopenic (o20 000/ml) and experienced epistaxis. Daily transfusions of thrombocytes and fresh-frozen plasma were needed. Cholestasic hepatopathy and positive CMV pp65 antigen test (43 positives/2 Â 10 5 PBL) and CMV PCR led to the diagnosis of primary CMV infection at the end of October 1998. Maintenance chemotherapy was interrupted and antiviral therapy was started alternating between ganciclovir and foscarnet. Although the CMV pp65 antigenaemia decreased (4 positives/2 Â 10 5 PBL), the pulmonary function deteriorated with subsequent intubation of the patient. A bronchoalveolar lavage was not performed. Adult respiratory distress syndrome developed followed by cardiovascular decompensation, leading to the patients death. Since autopsy was refused, organs involved in primary CMV infection could not be investigated and CMV strains could not be analysed. Therefore, it cannot totally be ruled out that CMV was transmitted by other routes.
This case demonstrates the need for careful assessment of the risks and benefits of granulocyte transfusion. The seronegative sister and prospective BM donor was excluded as the granulocyte donor due to the risk of alloimmunisation. Another CMV-seronegative donor was not available. Recently, it was shown that prophylactic granulocyte transfusions from CMV seropositive donors had little effect on the incidence of CMV viraemia in CMV seronegative recipients. 5 However, this case does not confirm these results. Here, fatal CMV disease developed despite virological screening and antiviral prophylaxis.
There is much debate about the choice of prophylactic antiviral agents in stem cell transplant. Some authors did not find a difference in the incidence of CMV disease between oral valacyclovir or i.v. acyclovir and i.v. ganciclovir given after engraftment. 6, 7 Others favour pp65 antigen-guided pre-emptive therapy with ganciclovir. 8 Furthermore, pre-emptive therapy with foscarnet was as efficacious as ganciclovir. 9 No recommendations are available for antiviral prophylaxis for a case such as this one. Ganciclovir or foscarnet are associated with myelosuppression or nephrotoxicity, hence the reason for not using them in this case. It should be emphasised that the risk of primary CMV infection may not always be foreseen because of falsenegative test results. 10 A recent follow-up study showed that only 36% of Medac-ELISA-seronegative healthy donors were confirmed by immunofluorescence test (in-house IFT) or Western blot (Mikrogen GmBH, Martinsried, Germany) to be CMV seronegative, whereas 64% turned out seropositive (G Bauer, personal communication). Therefore, we emphasise the importance of highly sensitive CMV serology of donor and recipient and frequent monitoring of high-risk patients. If CMV incompatibility cannot be avoided, we encourage antiviral prophylaxis with foscarnet for aplastic patients. 
